Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX) announced that interim data from its Phase 2b imaging trial of RAD101, a PET ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE